Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19.
Brandon J WebbWhitney BuckelTodd VentoAllison M ButlerNancy GriselSamuel M BrownIthan D PeltanEmily S SpivakMark ShahTheadora SakataAnthony WallinEddie StenehjemGreg PoulsenJoseph BledsoePublished in: Open forum infectious diseases (2021)
MAb treatment of high-risk ambulatory patients with early COVID-19 was well tolerated and likely effective at preventing the need for subsequent emergency department or hospital care.